RxDoctor Payments DataLook up a doctor →

Gina Mentzer, MD

Cardiovascular Disease · Lincoln, NENPI 1316168628

Payments from drug & device makers

$43,840in general payments, 2019–2025

Across 322 payments — averaging $136.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$17K
  • American Regent$15K
  • Boston Scientific$7K
  • E.r. Squibb & Sons, L.L.C.$420
  • Actelion Pharmaceuticals US, Inc.$398
  • Pfizer$334
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$3,18012%
  • Speaking & faculty fees$16,63062%
  • Travel & lodging$1,3155%
  • Food & beverage$5,59121%
  • Education$890%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,840 in reported general payments places this provider in the 80th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$237,770
Medicare patients
1,095
Services billed
4,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$98,340
XareltoRivaroxaban70$64,026
EntrestoSacubitril/Valsartan38$30,605
JardianceEmpagliflozin31$25,661
FarxigaDapagliflozin Propanediol25$18,623
Repatha SureclickEvolocumab16$12,506
Flecainide Acetate131$3,196
Torsemide144$2,939
Ranolazine ErRanolazine32$2,831
Metoprolol Succinate363$2,706
Amiodarone Hcl117$1,581
Midodrine Hcl40$1,517
Potassium Chloride79$1,418
Carvedilol175$1,399
Ezetimibe38$1,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$334$98,340136 claims
Johnson & JohnsonXarelto$258$64,02670 claims
NovartisEntresto$17,071$30,60538 claims
Boehringer IngelheimJardiance$326$25,66131 claims
AstraZenecaFarxiga$140$18,62325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →